Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

GSE263394 Dolutegravir induces FOLR1 expression during brain organoid development.
Contributors : Daniel Kraushaar ; Carlo Donato Caiaffa ; Robert M CabreraSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe brain and spinal cord are formed during neurulation, a developmental process that occurs during the first month of pregnancy and can be modified by low serum levels of folic acid (FA), environmental factors, or genetic predispositions. In 2018, data from a surveillance study in Botswana, a country with one of the highest incidences of human immunodeficiency virus (HIV) and lacking mandatory food folate fortification programs, revealed an increased risk of neur...
Source: GEO: Gene Expression Omnibus - April 10, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions
The use of T-cell re-directing therapy in multiple myeloma (MM) is promising. [1] Two chimeric antigen T cell receptor therapy (CAR-T) products: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) and three bispecific antibodies (BsAbs): (Teclistamab-cqyv, Talquetamab-tgvs, and Elranatamab-bcmm) are currently approved by the Food and Drug Administration (FDA) to use in relapsed/refractory (R/R) MM after receiving four or more prior lines of therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Samer Al Hadidi Tags: Editorial Source Type: research

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?
Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag. (Source: Thrombosis Research)
Source: Thrombosis Research - April 9, 2024 Category: Hematology Authors: Nicolas Gendron, Paul Billoir, Virginie Siguret, V éronique Le Cam-Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel De Maistre, Isabelle Gouin-Thibault, Georges Jourdi, French Society on Thrombosis and Haemostasis Source Type: research

SPOOC (Sensor for Periodic Observation of Choline): An Integrated Lab ‐on‐a‐Spoon Platform for At‐Home Quantification of Choline in Infant Formula
SPOOC, a fast, accurate, and wireless device, quantifies choline in infants' formulas in home settings. It utilizes laser-induced graphene as a platform for choline potentiometric detection and features a detachable potentiometric device that wirelessly transmits data to nearby smartphones. This device assists parents in ensuring infants receive sufficient choline, promoting better neural and muscular health. AbstractCholine is an essential micronutrient for infants' brain development and health. To ensure that infants receive the needed daily dose of choline, the U.S. Food and Drug Administration (FDA) has set requirement...
Source: Small - April 8, 2024 Category: Nanotechnology Authors: Abdulrahman Al ‐Shami, Farbod Amirghasemi, Ali Soleimani, Sina Khazaee Nejad, Victor Ong, Alara Berkmen, Alar Ainla, Maral P.S. Mousavi Tags: Research Article Source Type: research

Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research

Neural tissue tolerance to synthetic dural mater graft implantation in a rabbit durotomy model
This study evaluated the safety of ArtiFascia, a synthetic dura mater graft composed of poly(l-lactic-co-caprolactone acid) and poly(d-lactic-co-caprolactone acid), in a rabbit durotomy model. Previously, ArtiFascia demonstrated positive local tolerance and biodegradability in a 12-month preclinical trial. Here, specialized stains were used to evaluate potential brain damage associated with ArtiFascia use. Histochemical and immunohistochemical assessments included Luxol Fast Blue, cresyl Violet, Masson's Trichrome, neuronal nuclei,, Glial Fibrillary Acidic Protein, and ionized calcium-binding adaptor molecule 1 stains. The...
Source: Journal of Toxicologic Pathology - April 8, 2024 Category: Toxicology Authors: Yuval Ramot Noam Kronfeld Michal Steiner Nora Nseir Manassa Amir Bahar Abraham Nyska Source Type: research